Neurocysticercosis as an Eradicable Cause of Epilepsy: A Plan and Actions Are Needed

Hector H. Garcia; Armando E. Gonzalez; Robert H. Gilman

doi:10.1001/jamaneurol.2021.2349

Neurocysticercosis as an Eradicable Cause of Epilepsy: A Plan and Actions Are Needed

Hector H. Garcia, Armando E. Gonzalez, Robert H. Gilman

Producción científica: Contribución a una revista › Comentario/Debate

Idioma original	Inglés
Páginas (desde-hasta)	1045-1046
Número de páginas	2
Publicación	JAMA Neurology
Volumen	78
N.º	9
DOI	https://doi.org/10.1001/jamaneurol.2021.2349
Estado	Publicada - set. 2021
Publicado de forma externa	Sí

Acceder al documento

10.1001/jamaneurol.2021.2349

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

@article{70b19f4de8c94eb0bf85fffc10e309c0,

title = "Neurocysticercosis as an Eradicable Cause of Epilepsy: A Plan and Actions Are Needed",

author = "Garcia, {Hector H.} and Gonzalez, {Armando E.} and Gilman, {Robert H.}",

note = "Funding Information: reported grants from National Institute of Neurological Disorders and Stroke/National Institutes of Health for an unrelated clinical trial and a training grant from the Fogarty International Center/National Institutes of Health outside the submitted work. Dr Gilman reported nonfinancial support from Oxfendazole Development Group outside the submitted work. No other disclosures were reported.",

year = "2021",

month = sep,

doi = "10.1001/jamaneurol.2021.2349",

language = "Ingl{\'e}s",

volume = "78",

pages = "1045--1046",

journal = "JAMA Neurology",

issn = "2168-6149",

publisher = "American Medical Association",

number = "9",

}

TY - JOUR

T1 - Neurocysticercosis as an Eradicable Cause of Epilepsy

T2 - A Plan and Actions Are Needed

AU - Garcia, Hector H.

AU - Gonzalez, Armando E.

AU - Gilman, Robert H.

N1 - Funding Information: reported grants from National Institute of Neurological Disorders and Stroke/National Institutes of Health for an unrelated clinical trial and a training grant from the Fogarty International Center/National Institutes of Health outside the submitted work. Dr Gilman reported nonfinancial support from Oxfendazole Development Group outside the submitted work. No other disclosures were reported.

PY - 2021/9

Y1 - 2021/9

UR - http://www.scopus.com/inward/record.url?scp=85111388762&partnerID=8YFLogxK

U2 - 10.1001/jamaneurol.2021.2349

DO - 10.1001/jamaneurol.2021.2349

M3 - Comentario/Debate

AN - SCOPUS:85111388762

SN - 2168-6149

VL - 78

SP - 1045

EP - 1046

JO - JAMA Neurology

JF - JAMA Neurology

IS - 9

ER -